Highbridge Capital Management’s Gilead Sciences GILD Stock Holding History

Highbridge Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,400	Closed	-$383K	–	634
2018 Q2	$383K	Buy	+5,400	New	+$381K	0.01%	649
2018 Q1	–	Sell	-5,300	Closed	-$378K	–	1369
2017 Q4	$378K	Sell	5,300 -3,500	-40%	-$266K	0.01%	1085
2017 Q3	$712K	Buy	+8,800	New	+$673K	0.01%	747
2016 Q4	–	Sell	-11,000	Closed	-$871K	–	1374
2016 Q3	$871K	Buy	11,000 +7,600	+224%	+$617K	0.01%	606
2016 Q2	$283K	Buy	3,400 +400	+13%	+$35.5K	﹤0.01%	1094
2016 Q1	$277K	Buy	+3,000	New	+$271K	﹤0.01%	1210
2014 Q2	–	Sell	-5,500	Closed	-$390K	–	1145
2014 Q1	$390K	Buy	+5,500	New	+$431K	﹤0.01%	769
2013 Q3	–	Sell	-19,000	Closed	-$975K	–	1371
2013 Q2	$975K	Buy	+19,000	New	+$990K	0.01%	675

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Highbridge Capital Management's GILD Position: Q4 2018 in Review

Highbridge Capital Management sold out of Gilead Sciences (GILD) in Q4 2018, closing a stake of 31,541 shares — an estimated $2.44M sold.

Highbridge Capital Management first reported a position in GILD in Q2 2013 and held it in 18 quarters. The position peaked at $72.4M in Q4 2015. 1,497 funds tracked by Wall St. Rank hold GILD as of Q4 2018.

Highbridge Capital Management reported no remaining Gilead Sciences position as of Q4 2018 after selling out during the quarter.
Highbridge Capital Management sold 31,541 Gilead Sciences shares in Q4 2018, an estimated $2.44M.
Highbridge Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 18 quarters.
Highbridge Capital Management's Gilead Sciences position peaked at $72.4M in Q4 2015.
1,497 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.